AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01425073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinue TMP/SMZ prophylaxis
Description: Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
Study NCT03563703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
Study NCT03563703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Light
Description: Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
Study NCT00905021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg by mouth every day.
Study NCT00905021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent
Description: Sunitinib 37.5 mg by mouth every day.
Study NCT01806246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrative rehabilitation program
Study NCT04393636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital cardiac Counseling
Description: * Screening for reduced physical fitness and digital counseling.~* Screening for smoking and digital counseling.~* Screening for malnutrition and obesity and digital counseling.~* Screening for anxiety and depression and digital counseling.~* Screening for elevated pulmonary risk score and digital counseling.
Study NCT01680588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NAV4694
Study NCT03664622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
Study NCT03664622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
Study NCT00327665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23™
Description: Single-dose intramuscular injection.
Study NCT00327665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 intramuscular injection.
Study NCT00327665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-valent pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection
Study NCT02843295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Study NCT04802850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with movement
Study NCT03467555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class II correction using miniplates in zygomatic region
Study NCT01967654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical Assistance, training and clinical reminders
Study NCT01967654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Community Health Worker
Study NCT02176096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycosade
Study NCT04076202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Vanguard DD RP
Description: Patients treated with the Cementless Vanguard DD RP knee implant
Study NCT02618278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
Study NCT02618278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
Study NCT01421654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S9 Elite with Acclimate
Description: S9 Elite Flow Generator with Acclimate feature activated
Study NCT01421654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S9 Elite
Description: S9 Elite Flow Generator
Study NCT00299741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg daily, 4/2 schedule
Study NCT04336540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu configuration (presence of energy labelling)
Description: Restaurant menus are altered to accommodate energy labelling intervention
Study NCT04802850 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mulligan mobilization with movement
Study NCT00586924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study NCT04336540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu configuration (more lower energy options added)
Description: Restaurant menus are altered to include more lower energy options
Study NCT01671124 — intervention group
Intervention type: OTHER
Intervention: Soline capsule
Study NCT04157530 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: wang-bu-liu-xing
Description: wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
Study NCT04157530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture applied to Qingming and Qiuhou with Der-qi
Study NCT04157530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
Study NCT00628719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: a single dose of 10 mg/kg of liposomal amphotericin B
Study NCT00628719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphotericin B deoxycholate
Description: amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
Study NCT00586924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study NCT00586924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study NCT00586924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study NCT00586924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study NCT00586924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study NCT01249183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Concomitant administration
Description: 1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
Study NCT01249183 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Separate administration
Description: 1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK-0518)
Description: Raltegravir (MK-0518) 400 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Nevirapine (NVP) 200 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine (3TC) 150 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir disoproxil fumarate (TDF) 300 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Emtricitabine (FTC) 200 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir
Description: Lopinavir (LPV) 200 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir (r) 100 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Atazanavir (ATV) 300 mg tablets
Study NCT02116660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir (DAR) 400 mg tablets
Study NCT02893774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~* QLQ-C30~* SWLS (Satisfaction with Life Scale)~* PTGI (Post-Traumatic Growth Inventory)~* HADS (Hospital Anxiety and Depression Scale)~* Brief COPE~* MHLCS (Multidimensional Health Locus of Control Scale)
Study NCT03446534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Imacillin mixture
Study NCT03446534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo manufactured to mimic amoxicillin mixture (Imacillin)
Study NCT02763878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y anastomosis
Description: Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
Study NCT02763878 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Billroth II anastomosis
Description: Typical Billroth II anastomosis would be made after the Distal gastrectomy.
Study NCT00422838 — intervention group
Intervention type: PROCEDURE
Intervention: fine-needle aspiration biopsy
Description: aspiration of intrahepatic cells
Study NCT01517945 — intervention group
Intervention type: BEHAVIORAL
Intervention: AIM materials and assessments
Description: Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~* Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~* Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~* Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~* Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~* Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~* Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session.
Study NCT02681952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renamezin capsule
Study NCT02681952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kremezin granule
Study NCT03341546 — intervention group
Intervention type: OTHER
Intervention: A single measurement of the patient's abdominal depth
Description: A single measurement of the patient's anterior-posterior abdominal depth
Study NCT01001260 — intervention group
Intervention type: DRUG
Intervention: No ASA
Description: Alternative antiplatelet therapy instead of aspirin
Study NCT01001260 — intervention group
Intervention type: DRUG
Intervention: Low dose ASA
Description: Low dose aspirin (81mg) prior to PTCA
Study NCT01001260 — intervention group
Intervention type: DRUG
Intervention: 325 mg ASA
Description: high dose of aspirin prior to PTCA
Study NCT01832727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
Study NCT04050631 — intervention group
Intervention type: BEHAVIORAL
Intervention: maternal arrest simulation on L&D floor
Description: AFE on L\&D
Study NCT01215695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)
Description: The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
Study NCT01215695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
Study NCT05112354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic and intratympanic injection of steoid
Description: -If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator.
Study NCT00597103 — intervention group
Intervention type: OTHER
Intervention: Cognitive Function Testing-10 Tests
Description: Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
Study NCT01463150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150mg per day for 15 days
Study NCT01463150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 5mg per day for 15 days
Study NCT00864617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine Extended Release tablets 60 mg, single dose
Description: A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
Study NCT00864617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADALAT® CC Extended Release Tablets 60 mg
Description: B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
Study NCT01198834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-7EAT
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study NCT01198834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study NCT01198834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study NCT01198834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study NCT02676284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane SJ
Description: DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
Study NCT00597103 — intervention group
Intervention type: OTHER
Intervention: Sleep Assessment Testing
Description: Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously
Study NCT02088684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
Study NCT02088684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
Study NCT02088684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
Study NCT02088684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
Study NCT02315287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Comparison of two different thiazolidinediones
Study NCT02315287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobeglitazone
Description: Comparison of two different thiazolidinediones
Study NCT03854643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates group
Description: Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
Study NCT03854643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
Study NCT02912000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH intervention
Description: The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.